Torrent Pharma Q2 earnings: Profit declines 10% YoY to ₹534 crore, US revenue surges 24%

The company had posted a consolidated net profit of ₹591 crore in the corresponding period a year ago, Torrent Pharmaceuticals said in a regulatory filing.

Its total revenue from operations in the second quarter of the current fiscal year, however, rose sharply by 50.78% YoY to ₹4,979 crore during the quarter under review, compared with ₹3,302 crore in the July-September quarter of the 2025-26 fiscal year (Q2 FY26).

The total expenses in the quarter under review stood higher at ₹4,222 crore as compared to ₹2,471 crore in the year-ago period, the company said.

The company’s India revenue rose 20% YoY to ₹2,181 crore in Q2 FY27, while the US revenue increased 24% YoY to ₹417 crore.

Brazil revenue stood at ₹440 crore, up 38%, while the same for Germany dropped 7% YoY to ₹283 crore on a year-on-year basis.

Its operational EBITDA (earnings before interest, tax, depreciation, and amortisation) grew 53.8% YoY to ₹1,666 crore for the quarter ended September 30, 2026, as against ₹1,083 crore in Q2 FY26.

Its EBITDA margin expanded by 70 basis points (bps) YoY to 33.5% versus 32.8% in the year-ago period.

For the April-September period (H1 FY27), the company reported a consolidated net profit of ₹1,100 crore, down 3.42% YoY from ₹1,139 crore in the corresponding period of the preceding fiscal year, the filing added.

Torrent Pharma stock performance

Shares of Torrent Pharma closed 1.97% lower at ₹4,524.40 per unit on the National Stock Exchange (NSE) on Friday, October 23. However, the results were declared after the market closed.

The scrip has lost 1% in the past week and 9% over the month. However, on a year-to-date (YTD) basis, it has advanced more than 17%.

While the stock hit a 52-week high of ₹5,250 per equity share on August 3, 2026, it touched a year’s low of ₹3,532.60 apiece on November 6, 2026.

Torrent Pharmaceuticals has a total market capitalisation of ₹1.72 lakh crore as of October 23, 2026, according to data on the NSE.